Press release
Catalyst Biosciences Announces Oral and Poster Presentations at the World Federation of Hemophilia Virtual Summit 2020
SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced oral and poster presentations at the
About this update from Gyre Therapeutics, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced oral and poster presentations at the upcoming World Foundation of Hemophilia Virtual Summit, taking place from June 14-19, 2020.\n The poster abstract is now available online and can be accessed at https://www.wfh.org/virtual-summit/home. Presentation details: Poster Title:Phase 2b Trial to evaluate the safety and factor IX levels of a daily subcutaneous prophylaxis treatment regimen of dalcinonacog alfa in hemophilia BPresenting Author:Howard Levy, M.B.B.Ch., Ph.D., M.M.M., chief medical officer, Catalyst BiosciencesDate:June 14-19, 2020 Oral Title:Combination of a Novel Chimeric AAV Capsid and Potency Enhanced FIX Variant for Hemophilia B Gene TherapyPresenting Author:Grant E. Blouse, Ph.D., M.S., senior vice president of translational research, Catalyst BiosciencesDate/Time:June 19, 2020, 11:45 A.M. EDT The open-label Phase 2b study of dalcinonacog alfa (DalcA), a next-generation subcutaneously (SQ) administered Factor IX (FIX) for the treatment of hemophilia B was designed to evaluate daily SQ dosing and the ability to maintain protective steady state FIX levels above 12% in six individuals with severe hemophilia B. Each subject received a single intravenous dose, followed by daily SQ doses of DalcA for 28 days whereby the pharmacokinetics, pharmacodynamics, safety, tolerability and anti-drug antibody formation were monitored. In February 2020, Catalyst Biosciences reported positive interim efficacy and safety data from its Phase 2b trial in an oral presentation at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD). Dr. Blouse will present data from preclinical studies of Catalyst’s hemophilia B gene therapy CB 2679d-GT, a novel chimeric AAV capsid expressing the Company’s proprietary enhanced potency FIX variant that may reduce the vector dose required in gene therapy, while maintaining high FIX levels. A copy of the presentation materials can be accessed on the Events and Presentations section of the Catalyst website once the presentations conclude. About Catalyst BiosciencesCatalyst is a research and clinical development biopharmaceutical company focused on addressing unmet needs in rare hematologic and systemic complement-mediated disorders. Our protease ...